Skip Ribbon Commands
Skip to main content
Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

Now in effect: Preferred products for long- and short-acting colony-stimulating factors

April 1, 2021

​Independence is constantly evaluating our policies and industry trends to identify opportunities to make specialty drugs more affordable without limiting members' access to life-saving medications. As a result, Independence has changed how we manage the colony-stimulating factors (CSFs) drug class.

As of April 1, 2021, Independence designated the following CSF drugs as preferred products:

  • Long-acting CSFs
    • Fulphila® (pegfilgrastim-jmdb)
    • Neulasta® (pegfilgrastim)
    • Udenyca® (pegfilgrastim-cbqv)
  • Short-acting CSFs
    • Granix® (tbo-filgrastim)
    • Zarxio® (filgrastim-sndz)

To learn more about these changes and policy updates, please read our announcement article.

This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.